GSK drops Ebola vaccine development

Aug. 6, 2019

With limited profit prospects, GlaxoSmithKline is stopping work on three vaccines it was developing to fight against the Ebola and Marburg viruses. Instead, the vaccine candidates will be transferred to the Sabin Vaccine Institute with no financial element in the deal.

Sabin will continue to develop the candidate vaccines, including ChAd3, a potential Ebola shot that has been through mid-stage, Phase II, trials in Africa.

Previously, GSK put its Ebola vaccine work on hold after it was unable to progress the product through Phase III trials toward the end of the 2014-16 epidemic.

Read the Reuters report